The grades of five biotechnology stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an “A” (“strong buy”) or “B” overall (“buy”) rating.

This week, La Jolla Pharmaceutical Company (LJPC) is showing good progress as the company’s rating jumps from a B (“buy”) last week to an A (“strong buy”). In Portfolio Grader’s specific subcategories of Earnings Momentum and Earnings Revisions, LJPC also gets A’s. For more information, get Portfolio Grader’s complete analysis of LJPC stock.

Incyte Corporation (INCY) is bumping up its rating from a C (“hold”) to a B (“buy”) this week. Incyte is using its expertise in genomics and medicinal chemistry, as well as molecular, cellular, and in vivo biology to discover and develop novel therapeutics. For more information, get Portfolio Grader’s complete analysis of INCY stock.

Ambit Biosciences Corp.’s (AMBI) ratings are looking better this week, moving up to a B from last week’s C. For more information, get Portfolio Grader’s complete analysis of AMBI stock.

This is a strong week for Progenics Pharmaceuticals, Inc. (PGNX). The company’s rating climbs to B from the previous week’s C. Progenics Pharmaceuticals develops and distributes therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. Shares of the stock have been trading at an exceptionally rapid pace, up twofold from the week prior. For more information, get Portfolio Grader’s complete analysis of PGNX stock.

Celladon Corporation (CLDN) earns an A this week, jumping up from last week’s grade of B. For more information, get Portfolio Grader’s complete analysis of CLDN stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.